- cafead   Apr 20, 2023 at 11:02: AM
via Following a recent phase 2 failure, the San Francisco-based biotech company Nektar Therapeutics has slashed its workforce and axed the development of the protein drug rezpegaldesleukin (Rezpeg) for the treatment of the autoimmune disease systemic lupus erythematosus (SLE).
article source
article source